Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Populational analysis of the immunoglobulin G response to different COVID-19 vaccines in Brazil

Nigella M. Paula, Marcelo S. Conzentino, Ana C.A. Gonçalves, Renata da Silva, Karin V. Weissheimer, Carlos H.S. Kluge, Paulo H.S.A. Marins, Haxley S.C. Camargo, Lucas R.P. Farias, Thamyres P. Sant’Ana, Letícia R. Vargas, Juliane D. Aldrighi, Ênio S. Lima, Guiomar T. Jacotenski, Fabio O. Pedrosa, Alan G. Gonçalves, Emerson Joucoski, View ORCID ProfileLuciano F. Huergo
doi: https://doi.org/10.1101/2022.09.28.22280449
Nigella M. Paula
1Setor Litoral, Federal University of Parana - UFPR, Matinhos, PR, Brazil
2Graduated Program in Sciences – Biochemistry – UFPR, Curitiba, PR, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marcelo S. Conzentino
1Setor Litoral, Federal University of Parana - UFPR, Matinhos, PR, Brazil
2Graduated Program in Sciences – Biochemistry – UFPR, Curitiba, PR, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ana C.A. Gonçalves
1Setor Litoral, Federal University of Parana - UFPR, Matinhos, PR, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Renata da Silva
1Setor Litoral, Federal University of Parana - UFPR, Matinhos, PR, Brazil
2Graduated Program in Sciences – Biochemistry – UFPR, Curitiba, PR, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Karin V. Weissheimer
1Setor Litoral, Federal University of Parana - UFPR, Matinhos, PR, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carlos H.S. Kluge
1Setor Litoral, Federal University of Parana - UFPR, Matinhos, PR, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paulo H.S.A. Marins
1Setor Litoral, Federal University of Parana - UFPR, Matinhos, PR, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Haxley S.C. Camargo
1Setor Litoral, Federal University of Parana - UFPR, Matinhos, PR, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lucas R.P. Farias
1Setor Litoral, Federal University of Parana - UFPR, Matinhos, PR, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thamyres P. Sant’Ana
1Setor Litoral, Federal University of Parana - UFPR, Matinhos, PR, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Letícia R. Vargas
1Setor Litoral, Federal University of Parana - UFPR, Matinhos, PR, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Juliane D. Aldrighi
1Setor Litoral, Federal University of Parana - UFPR, Matinhos, PR, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ênio S. Lima
1Setor Litoral, Federal University of Parana - UFPR, Matinhos, PR, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Guiomar T. Jacotenski
1Setor Litoral, Federal University of Parana - UFPR, Matinhos, PR, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Fabio O. Pedrosa
2Graduated Program in Sciences – Biochemistry – UFPR, Curitiba, PR, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alan G. Gonçalves
1Setor Litoral, Federal University of Parana - UFPR, Matinhos, PR, Brazil
3Graduated Program in Farmacy – Biochemistry – UFPR, Curitiba, PR, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Emerson Joucoski
1Setor Litoral, Federal University of Parana - UFPR, Matinhos, PR, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Luciano F. Huergo
1Setor Litoral, Federal University of Parana - UFPR, Matinhos, PR, Brazil
2Graduated Program in Sciences – Biochemistry – UFPR, Curitiba, PR, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Luciano F. Huergo
  • For correspondence: huergo@ufpr.br luciano.huergo@gmail.com
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

Vaccination is a strategy that confers protection against symptomatic infections and/or development of severe COVID-19. In Brazil, COVID-19 vaccination began in January 2021 and has been performed using vaccines from different manufactures including CoronaVac (Sinovac), ChAdOx1 (Oxford/AstraZeneca) and BNT162b2 (Pfizer/BioNTech). One of the main protective mechanisms triggered by vaccination involves the production of IgG antibodies reactive to the Spike antigen of SARS-CoV-2, the levels of which correlates with vaccine efficacy. Although phase III clinical studies confirmed the efficacy of the vaccines used in Brazil, there are just few studies comparing vaccine immunogenicity in a real-world scenario. This study aimed to depict the IgG response to natural infections and to vaccination using different types of vaccines at population scale in Matinhos, a city located in south of Brazil. Nucleocapsid seroconversion rates indicated that more than a quarter of the cohort has been subjected to natural infections by SARS-CoV-2 by the first trimester of 2022. Spike seroconversion rates achieved >95% by February 2022 and maintained stable as far as June 2022 confirming the effectiveness of the vaccination program. Immunogenicity concerning IgG reactive to Spike was higher using the BNT162b2 vaccine, followed by ChAdOx1 and CoronaVac. Natural infections boosted IgG levels reactive to Spike in those individuals that completed primary vaccination with ChAdOx1 and CoronaVac but not with BNT162b2. The levels of IgG reactive to Spike increased with the number of vaccine doses administered. The application of BNT162b2 as booster dose resulted in high levels of IgG reactive to Spike which were similar despite the type of the vaccine used during primary vaccination.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This study was funded by Federal University of Parana

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Ethics approval was obtained from the CEP/UFPR (n# 35872520.8.0000.0102) and CEP/HEG (n# 54095221.0.0000.0098). Federal University of Parana

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

All data produced in the present study are available upon reasonable request to the authors

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted September 29, 2022.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Populational analysis of the immunoglobulin G response to different COVID-19 vaccines in Brazil
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Populational analysis of the immunoglobulin G response to different COVID-19 vaccines in Brazil
Nigella M. Paula, Marcelo S. Conzentino, Ana C.A. Gonçalves, Renata da Silva, Karin V. Weissheimer, Carlos H.S. Kluge, Paulo H.S.A. Marins, Haxley S.C. Camargo, Lucas R.P. Farias, Thamyres P. Sant’Ana, Letícia R. Vargas, Juliane D. Aldrighi, Ênio S. Lima, Guiomar T. Jacotenski, Fabio O. Pedrosa, Alan G. Gonçalves, Emerson Joucoski, Luciano F. Huergo
medRxiv 2022.09.28.22280449; doi: https://doi.org/10.1101/2022.09.28.22280449
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Populational analysis of the immunoglobulin G response to different COVID-19 vaccines in Brazil
Nigella M. Paula, Marcelo S. Conzentino, Ana C.A. Gonçalves, Renata da Silva, Karin V. Weissheimer, Carlos H.S. Kluge, Paulo H.S.A. Marins, Haxley S.C. Camargo, Lucas R.P. Farias, Thamyres P. Sant’Ana, Letícia R. Vargas, Juliane D. Aldrighi, Ênio S. Lima, Guiomar T. Jacotenski, Fabio O. Pedrosa, Alan G. Gonçalves, Emerson Joucoski, Luciano F. Huergo
medRxiv 2022.09.28.22280449; doi: https://doi.org/10.1101/2022.09.28.22280449

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (228)
  • Allergy and Immunology (506)
  • Anesthesia (110)
  • Cardiovascular Medicine (1245)
  • Dentistry and Oral Medicine (206)
  • Dermatology (147)
  • Emergency Medicine (282)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (534)
  • Epidemiology (10032)
  • Forensic Medicine (5)
  • Gastroenterology (500)
  • Genetic and Genomic Medicine (2466)
  • Geriatric Medicine (238)
  • Health Economics (480)
  • Health Informatics (1647)
  • Health Policy (754)
  • Health Systems and Quality Improvement (637)
  • Hematology (250)
  • HIV/AIDS (536)
  • Infectious Diseases (except HIV/AIDS) (11872)
  • Intensive Care and Critical Care Medicine (626)
  • Medical Education (253)
  • Medical Ethics (75)
  • Nephrology (268)
  • Neurology (2290)
  • Nursing (139)
  • Nutrition (352)
  • Obstetrics and Gynecology (454)
  • Occupational and Environmental Health (537)
  • Oncology (1249)
  • Ophthalmology (377)
  • Orthopedics (134)
  • Otolaryngology (226)
  • Pain Medicine (158)
  • Palliative Medicine (50)
  • Pathology (325)
  • Pediatrics (734)
  • Pharmacology and Therapeutics (315)
  • Primary Care Research (282)
  • Psychiatry and Clinical Psychology (2281)
  • Public and Global Health (4844)
  • Radiology and Imaging (843)
  • Rehabilitation Medicine and Physical Therapy (492)
  • Respiratory Medicine (652)
  • Rheumatology (286)
  • Sexual and Reproductive Health (241)
  • Sports Medicine (227)
  • Surgery (269)
  • Toxicology (44)
  • Transplantation (125)
  • Urology (99)